Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA: Supraphysiological Androgen to Enhance Treatment Activity
NCT06039371Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- May 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of testosterone cypionate in metastatic castration-resistant prostate cancer (mCRPC) (9 cohorts), sponsored by University of Washington. Primary endpoint: Prostate-Specific Antigen 50% Decline Response Rate up to 3 years. Started May 2024; status: recruiting.
02
Drugs
testosterone cypionate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06039371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039371.